4//SEC Filing
Xie Lan 4
Accession 0000899243-17-024251
CIK 0000880771other
Filed
Oct 15, 8:00 PM ET
Accepted
Oct 16, 5:07 PM ET
Size
26.0 KB
Accession
0000899243-17-024251
Insider Transaction Report
Form 4
Xie Lan
VP Finance China, CFO
Transactions
- Disposition to Issuer
Non-Qualified Stock Option (right to buy)
2017-10-13$6.66/sh−16,667$111,002→ 0 totalExercise: $4.52Exp: 2024-03-14→ Common Stock (16,667 underlying) - Exercise/Conversion
Restricted Stock Unit
2017-10-13−3,000→ 0 total→ Common Stock (3,000 underlying) - Exercise/Conversion
Restricted Stock Unit
2017-10-13−2,000→ 0 total→ Common Stock (2,000 underlying) - Disposition to Issuer
Common Stock
2017-10-13$11.18/sh−8,000$89,440→ 0 total - Exercise/Conversion
Restricted Stock Unit
2017-10-13−3,000→ 0 total→ Common Stock (3,000 underlying) - Disposition to Issuer
Non-Qualified Stock Option (right to buy)
2017-10-13$1.53/sh−21,000$32,130→ 0 totalExercise: $9.65Exp: 2027-03-08→ Common Stock (21,000 underlying) - Disposition to Issuer
Non-Qualified Stock Option (right to buy)
2017-10-13$6.65/sh−2,500$16,625→ 0 totalExercise: $4.53Exp: 2023-04-04→ Common Stock (2,500 underlying) - Exercise/Conversion
Common Stock
2017-10-13+8,000→ 8,000 total - Disposition to Issuer
Non-Qualified Stock Option (right to buy)
2017-10-13$2.35/sh−18,667$43,867→ 0 totalExercise: $8.83Exp: 2025-03-16→ Common Stock (18,667 underlying) - Disposition to Issuer
Non-Qualified Stock Option (right to buy)
2017-10-13$2.06/sh−28,000$57,680→ 0 totalExercise: $9.12Exp: 2026-03-15→ Common Stock (28,000 underlying)
Footnotes (10)
- [F1]Each restricted stock unit represented a contingent right to receive one share of SCLN common stock upon settlement.
- [F10]Under its terms the option became exercisable in installments with 25% vesting on March 8, 2018 and 2.0833% vesting each month thereafter until it became vested in full immediately prior to the Merger.
- [F2]Granted under Issuer's 2005 Equity Incentive Plan.
- [F3]Under its terms the option became exercisable in installments with 25% vesting on April 4, 2014 and 2.0833% vesting each month thereafter until it became vested in full on April 4, 2017.
- [F4]The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price.
- [F5]Under its terms the option became exercisable in installments with 25% vesting on March 14, 2015 and 2.0833% vesting each month thereafter until it became vested in full immediately prior to the Merger.
- [F6]Under its terms the option became exercisable in installments with 25% vesting on March 16, 2016 and 2.0833% vesting each month thereafter until it became vested in full immediately prior to the Merger.
- [F7]Restricted stock units became fully vested and entitled to settlement immediately prior to the Merger and terminated upon settlement in shares of SCLN common stock.
- [F8]Granted under Issuer's 2015 Equity Incentive Plan.
- [F9]Under its terms the option became exercisable in installments with 25% vesting on March 15, 2017 and 2.0833% vesting each month thereafter until it became vested in full immediately prior to the Merger.
Documents
Issuer
SCICLONE PHARMACEUTICALS INC
CIK 0000880771
Entity typeother
Related Parties
1- filerCIK 0001555794
Filing Metadata
- Form type
- 4
- Filed
- Oct 15, 8:00 PM ET
- Accepted
- Oct 16, 5:07 PM ET
- Size
- 26.0 KB